APOA1 and chronic myelogenous leukemia, BCR-ABL1 positive: The electrophoresis of the HDL showed that the treatment of CML with HDL caused a remarkable degradation of the HDL band intensity with a slight up-shift in the band position (lane 0) compared to native HDL (lane N), as shown in Figure 2B. On the other hand, the co-treatment of BWA caused notable protection of apoA-I from CML-mediated proteolytic degradation in a dose-dependent manner: up to ~1.5-fold and 1.3-fold stronger band intensities were achieved by treatment of the final 30 μM of BWA at 72 h and 144 h, respectively.